Molecular Targets of ADCs in Hematological Malignancies Hematological neoplasms are among the most common cancers worldwide; however, in recent decades, we have witnessed a decreasing trend in their mortality rate, which is undoubtedly related to the clinical development and commercialization of modern targeted therapies for their management [ 134 ].
← all excerpts
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.
1
—
—